Excellently written #CLML article about myeloma treatment in South Asia.
70% of #MMsm expenditures in 🇮🇳 🇵🇰 🇱🇰 🇧🇩 et al paid out of pocket by pts.
Over half of public institutions don't have access to FLC testing, let alone SPEP... We have work to do!
sciencedirect.com/science/articl…
This is directed at the authors, editors, and administrators of the WHO Blue Books:
1️⃣ If a chapter relies on genetic testing unavailable to >80% of the world, it serves no one but those who already know the disease. Rewrite it.
2️⃣ If you plan to change nomenclature, ask: Does it change practice? Does it impact clinical care? If not—don’t change it.
3️⃣ If you’re adding IHC to diagnostic criteria and it’s unavailable in most countries, don’t include it—unless you’re willing to pay for it.
4️⃣ Don’t create a new entity based solely on molecular testing if it’s not actionable and/or not visible on H&E.
5️⃣ For every chapter you write, ask yourself:
“Am I reducing global health inequity or increasing it?”
If the answer isn’t crystal clear, start over.
The vision and the visionary.
Prof @DrPMPGI has excellently conceived and lead a unique initiative in India to advance field of multiple myeloma research and care.
Kudos!
@IndMyAcGp#Image2025
Come January 2025 and, we await the next edition of the Indian Myeloma Congress by IMAGe (@IndMyAcGp). We have an exciting lineup of lectures and interactions with Who's Who of Myeloma. Know your faculty. #TMCKolkata#IndianMyelomaCongress2025
🚨 Join us for an exclusive webinar with Dr. Guilin Tang from MD Anderson Cancer Center on Optical Genome Mapping (OGM) in Hematological Disorders! 🚨
🗓️ Date: Aug 28, 2024 🕣 Time: 7:00 PM (IST) | 8:30 AM (Houston) 💻 Venue: Online
Register via QR code. Hosted by Hemat PGI CHD
CLPDs are often easy to diagnose by #flowcytometry, but every now & then comes a case that throws us off course. How do we approach these systematically? What markers are essential in our panels? Find out these & more from the experts at the #CLPD workshop at #FlowTCS2024!